FluoxymesteroneAlternative Names: Androfluorene; Androfluorone; Android-F; Androsterolo; Fluotestin; Fluoxymesterone CIII; Halotestin; Ora-Testryl; Oralsterone; Oratestin; Stenox; Testoral; Ultandren
Latest Information Update: 26 Aug 2004
At a glance
- Originator Unknown
- Developer Atlantil Labs; Bouty; Brown Pharmaceuticals; Novartis; Pfizer; Rosemont Pharmaceutical Corporation; Sanofi; Sanofy-Midy; Squibb
- Class Androstenediols; Fluorinated steroids; Small molecules; Testosterone congeners
- Mechanism of Action Testosterone agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Marketed Breast cancer; Delayed puberty; Hypogonadism